#USA #lipid nanoparticles #Hopkinton #Phosphorex #NOF Corporation

Phosphorex Announces Virtual Panel on Lipid Nanoparticles

In a significant move towards advancing drug delivery methods, Phosphorex LLC, in collaboration with notable members of the LNP Alliance—NOF Corporation and NeoSome Life Sciences—is set to host a complimentary one-hour virtual panel discussion titled "Streamline Targeted LNP Development to Improve Preclinical Translation" on July 29, 2026. This session aims to provide insights into the challenges and innovative strategies related to the development of targeted lipid nanoparticles (LNPs).

Lipid nanoparticles have emerged as essential vehicles for nucleic acid delivery, yet their propensity to aggregate in the liver has limited their therapeutic utility across various applications. During this engaging session, a panel of seasoned scientists will share their expertise on how iterative formulation optimization can enhance the quality attributes of LNPs, ensuring their functionality and manufacturability.

Expert Insights

The discussion will be moderated by Dr. Allen Horhota, a distinguished expert with nearly two decades of experience in RNA therapeutics and who previously served as the Vice President of Platform and Delivery at Seamless Therapeutics. He will be joined by fellow experts including:

• - Dr. Nicholas Boylan: Senior Director of Scientific Services at Phosphorex, who brings extensive knowledge in formulation chemistry.
• - Dr. Syed Reza: MD-PhD, who leads External Innovation and Alliance Management at NOF Corporation, offering perspectives on pharmaceutical innovations.
• - Dr. Michelle Bellerose: Study Director at NeoSome Life Sciences, who specializes in preclinical research and drug development.

This panel aims to equip scientists, formulation researchers, and development teams with a practical framework for transitioning ligand-conjugated LNPs from formulation stages through to preclinical validation. Key strategies including the incorporation of ligands via covalent conjugation and post-insertion methods will be discussed, providing valuable insights into enhancing nanoparticle stability and performance while optimizing their delivery capabilities.

Registration and Access

Interested participants can register for free at xtalks.com. Don't miss this opportunity to engage with experts and enhance your understanding of lipid nanoparticle technology.

About Phosphorex

Founded in 2005 and headquartered in Hopkinton, Massachusetts, Phosphorex specializes in the development of particulate drug delivery systems. Their expertise spans lipid nanoparticles, polymeric nanoparticles, and polymeric microsphere formulation, contributing to a wide range of therapeutic programs from early development to clinical translation. For more details about Phosphorex and their innovative approaches, visit www.phosphorex.com or follow them on LinkedIn.

Additional Partner Information

NOF Corporation has been at the forefront of technological innovation in the pharmaceutical sector, providing high-purity phospholipids, diacylglycerol PEGs, and proprietary ionizable lipids. Learn more at www.nof.co.jp.

NeoSome Life Sciences focuses on advancing drug discovery through personalized research services. For detailed information on their offerings, visit neosomels.com.

By participating in this virtual discussion, attendees will gain invaluable insights into the future of targeted drug delivery, making it a must-attend event for professionals in the field.